News
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...
Alright, listen to me. This one is one that everyone’s going to give up on. Then one day, it’s going to be up 300, I’m not ...
President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...
Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...
A new $5.5 million grant will fund STEM programs and career pathways for IPS middle and high school students starting at ...
20hon MSN
President Trump announced potential tariffs on imported pharmaceuticals by month's end, followed by semiconductor levies.
President Donald Trump says that he was likely to impose tariffs on pharmaceuticals as soon as the end of this month.
GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the ...
President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...
A Nigerian-born health data scientist, David Ajayi, is making waves in the United States through nationally recognized work ...
Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results